BSE Live
Apr 02, 16:01Prev. Close
44.98
Open Price
44.30
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 02, 15:59Prev. Close
44.53
Open Price
45.86
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
53.38 (100)
| Key Financial Ratios of Brooks Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 1.14 | 0.58 | -3.32 | 0.27 | -6.31 | |
| Diluted EPS (Rs.) | 1.14 | 0.58 | -3.32 | 0.27 | -6.31 | |
| Cash EPS (Rs.) | 1.58 | 1.26 | -2.62 | 0.87 | -3.44 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 39.06 | 26.49 | 22.98 | 26.31 | 25.99 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 39.06 | 26.49 | 22.98 | 26.31 | 25.99 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 28.03 | 30.28 | 22.48 | 31.16 | 31.27 | |
| PBDIT/Share (Rs.) | 1.99 | 1.59 | -2.31 | 1.14 | 0.71 | |
| PBIT/Share (Rs.) | 1.44 | 0.91 | -3.01 | 0.54 | -2.16 | |
| PBT/Share (Rs.) | 1.10 | 0.59 | -3.32 | 0.27 | -3.41 | |
| Net Profit/Share (Rs.) | 1.04 | 0.58 | -3.32 | 0.27 | -6.31 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 7.09 | 5.24 | -10.27 | 3.66 | 2.26 | |
| PBIT Margin (%) | 5.15 | 3.01 | -13.36 | 1.73 | -6.91 | |
| PBT Margin (%) | 3.90 | 1.95 | -14.74 | 0.86 | -10.91 | |
| Net Profit Margin (%) | 3.69 | 1.92 | -14.74 | 0.86 | -20.17 | |
| Return on Networth / Equity (%) | 2.65 | 2.19 | -14.42 | 1.02 | -24.27 | |
| Return on Capital Employed (%) | 3.61 | 3.36 | -12.49 | 1.96 | -7.94 | |
| Return on Assets (%) | 2.16 | 1.61 | -8.86 | 0.64 | -16.76 | |
| Total Debt/Equity (X) | 0.05 | 0.07 | 0.10 | 0.08 | 0.13 | |
| Asset Turnover Ratio (%) | 0.70 | 0.85 | 0.57 | 0.78 | 83.06 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.48 | 1.35 | 0.84 | 1.04 | 1.08 | |
| Quick Ratio (X) | 1.08 | 0.93 | 0.49 | 0.58 | 0.60 | |
| Inventory Turnover Ratio (X) | 8.78 | 4.28 | 2.32 | 3.21 | 6.24 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 322.19 | 247.92 | 159.23 | 183.19 | 160.81 | |
| EV/Net Operating Revenue (X) | 3.90 | 3.12 | 2.87 | 2.38 | 2.08 | |
| EV/EBITDA (X) | 55.01 | 59.41 | -27.90 | 64.91 | 91.80 | |
| MarketCap/Net Operating Revenue (X) | 3.84 | 3.06 | 2.78 | 2.33 | 1.99 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 2.76 | 3.50 | 2.72 | 2.76 | 2.39 | |
| Price/Net Operating Revenue | 3.84 | 3.06 | 2.78 | 2.33 | 1.99 | |
| Earnings Yield | 0.01 | 0.01 | -0.05 | 0.00 | -0.10 |
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth